Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

NCT04506645 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: REGN5381
OTHER: Placebo

Sponsor

Regeneron Pharmaceuticals